

CD8 alpha&beta Heterodimer

Catalog # PVGS1918

Product Information

Primary Accession Species	P01732-1(CD8 alpha)&P10966-1(CD8 beta) Human
Sequence	Ser22-Asp182(CD8 alpha) acidic tail and Leu22-Pro170(CD8 beta) basic tail
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Measured by its binding ability in a functional ELISA. Immobilized CD8 alpha&beta Heterodimer, His & Flag, Human at 2 μ g/ml (100 μ l/well) on the plate can bind Anti-CD8 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System	HEK293
Theoretical Molecular Weight	23.54 kDa (CD8 alpha) and 22.62 kDa (CD8 beta)
Formulation Reconstitution	Lyophilized from a 0.22 μ m filtered solution in PBS, (pH 7.4). Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μ g/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	CD8 alpha&beta (CD8 $\alpha\beta$) is a heterodimeric form of CD8. CD8 α is required for surface expression of CD8 β . The extracellular IgV-like domain of CD8 α interacts with the α 3 portion of the class I MHC molecule. CD8 $\alpha\beta$ is expressed on human peripheral T cells and functions as a coreceptor and can greatly increase the sensitivity and breadth of antigen recognition by CD8+ peripheral T cells bearing TCR.
--------------------------	--

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.